DCN Dx, a US-based company that deals with the end-to-end development, manufacturing, and commercialisation of point-of-use tests, announced on Wednesday that it has entered into a subcontract agreement with Mapp Biopharmaceutical, Inc., a US-based developer of novel pharmaceuticals for the prevention and treatment of infectious disease.

The subcontract covers the development, optimisation, and deployment of a digitised lateral flow assay to detect circulating Sudan ebolavirus (SUDV) antigen for real-time use in nonclinical studies taking place within biosafety level 4 (BSL4/ABSL4) containment laboratories.

Mitzi Rettinger, DCN Dx's chief revenue officer, said, 'DCN Dx is proud to partner with Mapp Biopharmaceutical to develop medical countermeasures for SUDV. This digitised lateral flow assay will be among the first to offer rapid, cage-side detection of SUDV antigens in nonclinical studies.'